Form 4: Phathom Pharma Director Exercises Options

Phathom Pharmaceuticals director Asit Parikh exercised options to acquire 8,750 shares of common stock at $10.30 per share in a pre-planned transaction.

Summary

• Asit Parikh, a Director of Phathom Pharmaceuticals, Inc. (PHAT), acquired 8,750 shares of common stock.
• The acquisition occurred on December 19, 2025, through the exercise of a "Right to Buy" derivative security.
• The exercise price for these shares was $10.30 per share.
• Following this transaction, Mr. Parikh directly beneficially owns 122,250 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract.
• Mr. Parikh continues to hold 8,750 derivative securities (Rights to Buy) with an exercise price of $10.30, exercisable from May 23, 2025, and expiring on May 22, 2034.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (option exercise) by a director. It is neutral in sentiment as it reflects a standard compensation event rather than a significant positive or negative operational or strategic development.

Positives

• Director Asit Parikh increased his direct ownership in Phathom Pharmaceuticals by acquiring 8,750 shares, which can be interpreted as a signal of confidence in the company's future prospects.
• The transaction was pre-planned under Rule 10b5-1(c), indicating a structured approach to insider trading and reducing concerns about opportunistic timing.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

This is a routine insider transaction for a pharmaceutical company. Such transactions are common as part of executive compensation and long-term incentive plans. It does not directly relate to broader industry trends, but rather to individual executive compensation and equity ownership.

Comparison to Industry Standards

• This filing reports a standard option exercise by a director, which is a common component of executive compensation across industries, including pharmaceuticals. No specific comparable companies or projects are relevant here.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by Director Asit Parikh through the exercise of derivative securities is a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as a sign of confidence, but the transaction itself is a routine compensation event and does not necessarily imply new fundamental information.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned option exercise by a director. While an increase in insider ownership can be a positive signal, this specific transaction is part of a compensation plan and does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It is an expected event for an insider.

Keywords

Phathom Pharmaceuticals, PHAT, Asit Parikh, Director, SEC Form 4, insider transaction, stock options, equity acquisition, 10b5-1 plan